Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
There is no FDA or EMA approval for the use of Fidaxomicin + Vancomycin as a combination therapy for Clostridioides difficile infection (CDI) (recurrent). Both Fidaxomicin and Vancomycin are individually approved by the FDA and EMA for the treatment of CDI, including recurrent cases, but neither agency has approved their simultaneous use as a fixed combination or sequential therapy for this indication.
see also:
[Antibiotics & Clostridioides difficile infection (CDI…